The SA study data were used to evaluate the safety of the vaccine in the results just published, but not the efficacy (percentage reduction of disease). The authors also report on an extensive safety database from volunteers in the UK, Brazil and South Africa accompanying the efficacy findings. Oxford-AstraZeneca vaccine more accessible than mRNA vaccines“This Covid-19 vaccine has the greatest prospect of being deployed in low- and middle-income countries in the immediate future compared to the mRNA Covid-19 vaccines,” said Madhi. This was done through the use of weekly swabbing by UK trial volunteers. According to the data, the standard (low) dose vaccine may provide protection against asymptomatic infection.

Source: News 24 December 09, 2020 11:11 UTC